Does the media favor INO or MRNA?

In the previous week, Moderna had 47 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 48 mentions for Moderna and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Moderna's score of 0.33 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 11 Very Positive mention(s) 16 Positive mention(s) 12 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ENTX or INO more profitable?

Entera Bio's return on equity of -147.19% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media refer more to ENTX or INO?

In the previous week, Entera Bio had 4 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 5 mentions for Entera Bio and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Entera Bio's score of 0.54 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INO or MPLT more profitable?

Maplight Therapeutics' return on equity of -98.60% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Maplight Therapeutics N/A -98.60% -60.33%

Does the media prefer INO or KMDA?

In the previous week, Kamada had 15 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 16 mentions for Kamada and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Kamada's score of -0.30 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PBYI or INO?

In the previous week, Puma Biotechnology and Puma Biotechnology both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Puma Biotechnology's score of 0.52 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inovio Pharmaceuticals (INO) Competitors

$1.21 -0.01 (-0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.21 0.00 (0.00%)

As of 07:59 PM Eastern

Compare

INO vs. MRNA, ENTX, MPLT, KMDA, and PBYI

Should you buy Inovio Pharmaceuticals stock or one of its competitors? Inovio Pharmaceuticals's main competitors and comparable companies include Moderna (MRNA), Entera Bio (ENTX), Maplight Therapeutics (MPLT), Kamada (KMDA), and Puma Biotechnology (PBYI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inovio Pharmaceuticals compare to Moderna?

Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Inovio Pharmaceuticals currently has a consensus price target of $3.17, indicating a potential upside of 161.71%. Moderna has a consensus price target of $77.83, indicating a potential downside of 58.81%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,085.23	-$84.95M	-$0.91	N/A
Moderna	$1.94B	38.80	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 47 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 48 mentions for Moderna and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Moderna's score of 0.33 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	11 Very Positive mention(s)	16 Positive mention(s)	12 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Moderna has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Inovio Pharmaceuticals beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Entera Bio has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Entera Bio has higher earnings, but lower revenue than Inovio Pharmaceuticals. Entera Bio is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,565.72	-$11.44M	-$0.35	N/A
Inovio Pharmaceuticals	$60K	2,085.23	-$84.95M	-$0.91	N/A

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 10.6% of Entera Bio shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Entera Bio had 4 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 5 mentions for Entera Bio and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Entera Bio's score of 0.54 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entera Bio currently has a consensus price target of $9.60, suggesting a potential upside of 232.18%. Inovio Pharmaceuticals has a consensus price target of $3.17, suggesting a potential upside of 161.71%. Given Entera Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Entera Bio's return on equity of -147.19% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Summary

Entera Bio beats Inovio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Maplight Therapeutics?

Inovio Pharmaceuticals (NASDAQ:INO) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 1 mentions for Inovio Pharmaceuticals and 0 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 1.82 beat Inovio Pharmaceuticals' score of 1.10 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Inovio Pharmaceuticals	Positive
Maplight Therapeutics	Very Positive

Inovio Pharmaceuticals has higher revenue and earnings than Maplight Therapeutics. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,085.23	-$84.95M	-$0.91	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

Maplight Therapeutics' return on equity of -98.60% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Inovio Pharmaceuticals currently has a consensus target price of $3.17, indicating a potential upside of 161.71%. Maplight Therapeutics has a consensus target price of $29.50, indicating a potential upside of 206.33%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maplight Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Maplight Therapeutics beats Inovio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Kamada?

Inovio Pharmaceuticals (NASDAQ:INO) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Inovio Pharmaceuticals currently has a consensus price target of $3.17, suggesting a potential upside of 161.71%. Kamada has a consensus price target of $13.50, suggesting a potential upside of 64.63%. Given Inovio Pharmaceuticals' higher possible upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,085.23	-$84.95M	-$0.91	N/A
Kamada	$180.46M	2.61	$20.20M	$0.38	21.58

Kamada has a net margin of 11.60% compared to Inovio Pharmaceuticals' net margin of 0.00%. Kamada's return on equity of 8.37% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Kamada	11.60%	8.37%	5.85%

Inovio Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Kamada has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Kamada had 15 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 16 mentions for Kamada and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Kamada's score of -0.30 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kamada beats Inovio Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Inovio Pharmaceuticals compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Puma Biotechnology currently has a consensus target price of $6.00, indicating a potential downside of 39.02%. Inovio Pharmaceuticals has a consensus target price of $3.17, indicating a potential upside of 161.71%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Puma Biotechnology has a net margin of 11.50% compared to Inovio Pharmaceuticals' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Puma Biotechnology has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Puma Biotechnology and Puma Biotechnology both had 1 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Puma Biotechnology's score of 0.52 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inovio Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.22	$31.11M	$0.52	18.92
Inovio Pharmaceuticals	$60K	2,085.23	-$84.95M	-$0.91	N/A

Summary

Puma Biotechnology beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Inovio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INO vs. The Competition

Export

Metric	Inovio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$126.14M	$3.94B	$7.23B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.87%
P/E Ratio	-1.33	7.98	213.54	21.25
Price / Sales	2,085.23	1,293.92	607.24	91.04
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	3.36	15.66	10.51	6.26
Net Income	-$84.95M	-$22.67M	$3.50B	$360.95M
7 Day Performance	N/A	-3.44%	-2.48%	-1.89%
1 Month Performance	-9.02%	-9.36%	-5.65%	-3.43%
1 Year Performance	-48.95%	22.41%	9.54%	2.60%

Inovio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INO Inovio Pharmaceuticals	3.0492 of 5 stars	$1.21 -0.8%	$3.17 +161.7%	-47.9%	$126.14M	$60K	N/A	112
MRNA Moderna	1.9511 of 5 stars	$167.77 +8.9%	$76.72 -54.3%	+645.5%	$67.17B	$2.21B	N/A	4,700	Trending News Analyst Downgrade Gap Down
ENTX Entera Bio	3.6082 of 5 stars	$2.93 -1.2%	$9.00 +207.7%	+51.6%	$510.37M	$40K	N/A	21	Gap Up
MPLT Maplight Therapeutics	3.8575 of 5 stars	$10.95 +0.3%	$29.50 +169.5%	N/A	$507.35M	N/A	N/A	133
KMDA Kamada	4.8921 of 5 stars	$8.82 -0.3%	$13.50 +53.1%	+21.9%	$507.24M	$180.46M	23.21	462	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INO) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ENTX, MPLT, KMDA, and PBYI

How does Inovio Pharmaceuticals compare to Moderna?

Summary

How does Inovio Pharmaceuticals compare to Entera Bio?

Summary

How does Inovio Pharmaceuticals compare to Maplight Therapeutics?

Summary

How does Inovio Pharmaceuticals compare to Kamada?

Summary

How does Inovio Pharmaceuticals compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inovio Pharmaceuticals (INO) Competitors

INO vs. MRNA, ENTX, MPLT, KMDA, and PBYI

How does Inovio Pharmaceuticals compare to Moderna?

Do analysts rate INO or MRNA?

Do institutionals and insiders believe in INO or MRNA?

Which has better valuation and earnings, INO or MRNA?

Does the media favor INO or MRNA?

Which has more risk and volatility, INO or MRNA?

Is INO or MRNA more profitable?

Summary

How does Inovio Pharmaceuticals compare to Entera Bio?

Which has more risk & volatility, ENTX or INO?

Which has better valuation and earnings, ENTX or INO?

Do institutionals & insiders hold more shares of ENTX or INO?

Does the media refer more to ENTX or INO?

Do analysts recommend ENTX or INO?

Is ENTX or INO more profitable?

Summary

How does Inovio Pharmaceuticals compare to Maplight Therapeutics?

Does the media favor INO or MPLT?

Which has higher valuation and earnings, INO or MPLT?

Is INO or MPLT more profitable?

Do analysts recommend INO or MPLT?

Do institutionals & insiders believe in INO or MPLT?

Summary

How does Inovio Pharmaceuticals compare to Kamada?

Do analysts rate INO or KMDA?

Which has preferable earnings & valuation, INO or KMDA?

Is INO or KMDA more profitable?

Which has more risk and volatility, INO or KMDA?

Do insiders & institutionals hold more shares of INO or KMDA?

Does the media prefer INO or KMDA?

Summary

How does Inovio Pharmaceuticals compare to Puma Biotechnology?

Do insiders and institutionals believe in PBYI or INO?

Do analysts rate PBYI or INO?

Is PBYI or INO more profitable?

Which has more volatility and risk, PBYI or INO?

Does the media refer more to PBYI or INO?

Which has higher valuation & earnings, PBYI or INO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INO vs. The Competition

Inovio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools